Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasms 2Leukemia, Myeloid 2Bronchiolitis Obliterans Syndrome 1

Interventions

Imatinib Mesylate 8venetoclax 6Cytarabine 5ponatinib 4nilotinib 4Azacitidine 4zosuquidar trihydrochloride 2fludarabine 2bosutinib 2RO6839921 2Decitabine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1pulrodemstat besilate 1posaconazole 1pegfilgrastim 1lestaurtinib 1gilteritinib 1flumatinib 1enasidenib 1emvododstat 1blinatumomab 1asciminib 1Whole-Body Irradiation 1N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1Lenalidomide 1Immunotherapy, Adoptive 1Idarubicin 1IMC-EB10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid × RO6839921 × Clear all
NCT02098967 2018-05-17

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Hoffmann-La Roche

Phase 1 Completed
68 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms

NCT01677780 2017-07-07

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Hoffmann-La Roche

Phase 1 Completed
11 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡